IMS: merger with TPG/CPPIB on track

IMS Health convened a special meeting to vote on its buyout offer, in what some consider a move to restore investor confidence in the deal.

At the Feb. 8 meeting, stockholders will be entitled to vote on the buyout. At press time, an IMS spokesman told MM&M that the final proxy was filed with SEC on Dec. 29, and that the company still believes the transaction will be completed by the end of the first quarter.

IMS shares plunged in December after reports swirled of a possible congressional amendment banning the collection of physicians' prescribing data for marketing purposes, a proposal which analysts said may have imperiled IMS's buyout deal.

The planned takeover by investment funds TPG Capital and CPP Investment Board, announced in November, is valued at $5.2 billion, including assumed debt.
You must be a registered member of MMM to post a comment.

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.